Usefulness of rh-G-CSF in early-onset severe neutropenia in neonatal lupus syndrome.
Neutropenia is a mild and transient manifestation of neonatal lupus syndrome (NLS) in the second or third month of life. The authors describe a newborn with an early-onset severe neutropenia due to anti-Ro/SSA. In the second day of life, neutropenia has been treated with recombinant human granulocyte colony-stimulating factor (rh-G-CSF). This is the first case in which rh-G-CSF was used in NLS, and the authors studied the pharmacologic action of the drug in relationship to the pathophysiology of NLS.
Zuppa
Antonio Alberto
AA
Department of Pediatrics, Division of Neonatology, Catholic University of the Sacred Heart, Rome, Italy. zuppaaa@rm.unicatt.it
De Luca
Daniele
D
De Turris
Pierluigi
P
Cota
Francesco
F
Tortorolo
Guiseppe
G
D000974:Antibodies, Antinuclear / Q000032:analysis; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D008180:Lupus Erythematosus, Systemic / Q000151:congenital* / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D009503:Neutropenia / Q000188:drug therapy* / Q000209:etiology; D011994:Recombinant Proteins
D000974:Antibodies, Antinuclear; D011994:Recombinant Proteins; C035356:SS-A antibodies; D016179:Granulocyte Colony-Stimulating Factor